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treatment effect on platelet count and complications were 
evaluated.
Results Despite a comparable volume of the processed 
plasma, mTPE treatment time was 10.5 % longer than 
cTPE treatment time (p < 0.05), resulting in a 10 % lower 
plasma removal rate of the mTPE treatment. Both treat-
ments were comparable in terms of decrease in median 
(IQR) IgG [pre-mTPE 5.34 (3.48–8.37), post-mTPE 1.96 
(1.43–2.84) g/L; pre-cTPE 5.88 (3.42–8.84), post-cTPE 
1.89 (1.21–3.52) g/L]. Also the median (IQR) amount of 
IgG removed in mTPE [13.14 (7.42–16.10) g] was not dif-
ferent from the cTPE treatment [9.30 (6.26–15.69) g]. This 
was also true for IgM removal. Platelet loss during mTPE 
was nearly twice as much as with cTPE (15 ± 9 versus 
7 ± 9 %, p < 0.05).
Conclusion Although the centrifugal procedures were 
conducted using flow rates that could easily be obtained 
using peripheral access, plasma removal efficiency was sig-
nificantly higher and treatment time was significantly lower 
in cTPE as compared to mTPE. Despite this lower treat-
ment time, the decline in markers of procedure efficacy was 
comparable. Especially in centers performing many proce-
dures per year, cTPE in contrast to mTPE can reduce treat-
ment time without compromising treatment efficacy.
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Introduction
Therapeutic plasma exchange (TPE) is an extracorporeal 
blood purification technique that was first described in 1914 
[1]. It removes pathogenic substances such as autoantibod-
ies, lipoproteins and circulating immune complexes from 
Abstract 
Background Therapeutic plasma exchange (TPE) is either 
performed using a highly permeable filter with standard 
multifunctional renal replacement equipment (mTPE) or a 
centrifugation device (cTPE). Although both techniques are 
well established in clinical practice, performance of these 
two modes of TPE was never compared in a prospective 
randomized fashion. Thus we aimed to compare two com-
mercially available therapeutic apheresis systems: mTPE 
(Octonova with Plasmaflo filter) and cTPE (Spectra Optia 
apheresis system).
Methods Twenty-one patients (age 51.6 ± 13.5 years; 10 
F/11 M; BMI 25.1 ± 5.0 kg/m2) were enrolled in this ran-
domized, prospective, paired, crossover study performed 
in the Hannover Medical School, Germany. First treatment 
(either mTPE or cTPE) was chosen by an online randomi-
zation list. The primary endpoints were plasma removal 
efficiency with 1.2× of the total plasma volume exchanged. 
Secondary endpoints were total amount of plasma sub-
stances removed, such as IgG and fibrinogen. Further, the 
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the plasma [9] and plays a key role in the management of 
various diseases. According to the 2013 guidelines of the 
American Society of Apheresis, it is the treatment of choice 
for acute ANCA-associated rapid progressive glomerulo-
nephritis, thrombotic thrombocytopenic purpura, Guillian–
Barré syndrome, Goodpasture’s syndrome and cardiac allo-
graft rejection [13]. Especially in the transplant setting and 
in patients with neurological disease, treatment numbers 
are increasing [5, 11]. TPE continues to be used in indica-
tions being far from established like during the 2011 Ger-
man STEC-HUS crisis [6] or in sepsis [4]. At our institu-
tion alone, the number of annual TPEs increased from 190 
treatments in 2004 to 1215 treatments in 2014. There are 
two well-established modes to perform TPE using either a 
highly permeable filter with (mTPE) in conjunction with a 
multifunctional hemofiltration/dialysis device or a centrifu-
gation device (cTPE) whose operation mode is limited to 
apheresis and cell collection. It is viewed as the preferred 
mode for the treatment of septic patients [14]. While mTPE 
is preferred by nephrology departments as a management 
option in the treatment of autoimmune-related renal dis-
eases such as microangiopathic hemolytic anemias, cTPE 
is preferentially used in transfusion medicine for a variety 
of diseases in the field of nephrology, neurology and hema-
tology. According to the 2007 International Apheresis Reg-
istry, surveys of apheresis have shown geographical differ-
ences of clinical practice and the type of technologies used 
[7]. Plasma treatment by membrane filtration is preferred 
both in Germany and Japan. By contrast, in the USA, TPE 
is primarily performed by centrifugation. Even though the 
differences between mTPE and cTPE had been extensively 
discussed in review papers over the last decades [3, 16], a 
head-to-head comparison of these two techniques in regard 
to the duration of treatment and effectiveness of separation 
does so far not exist. Thus, we designed a randomized pro-
spective trial to test effectiveness of both techniques to per-
form the first ever controlled comparison of both techniques.
Patients and methods
The study was approved by the local ethics committee of 
Hannover Medical School, Germany, protocol #5343. All 
patients gave written informed consent before enrollment 
into the study.
Study design
This was a prospective, open-label, randomized, crosso-
ver study to compare mTPE using the OctoNova (Diamed, 
Cologne, Germany) device with the Plasmaflo OP 05W 
(Asahi Kasei Medical, Japan) filter to cTPE using the Spec-
tra Optia (Terumo BCT, Lakewood, CO, USA) apheresis 
device. The study setting was the critical care nephrology 
unit of a tertiary care hospital.
Study protocol
This study included 21 patients with the need for TPE as 
reported elsewhere [12]. The inclusion criteria were:
(1) Indication for TPE; (2) age between 18 and 80 years; 
and (3) written informed consent. Exclusion criteria were: 
(1) need for fresh-frozen plasma as replacement fluid and 
(2) participation in another study. Albumin solution was 
individually and freshly made up immediately before TPE 
by mixing 20 % albumin solution (100 ml bottles) and 
Duosol® a ready-to-use bicarbonate dialysate solution (B. 
Braun, Melsungen, Germany) containing 2 mmol/L potas-
sium to yield the calculated volume of replacement fluid.
The device for the first treatment was allocated by ran-
domization (automatically online generated). After the first 
TPE either with membrane or centrifuge technique, the sec-
ond TPE was done in a crossover design, i.e., switch to the 
other technique. For patients who underwent more than two 
TPEs, only the first two treatments were recorded. Patient 
selection was restricted to those that received albumin as 
replacement fluid, to allow the measurement of plasma con-
stituents in the removed plasma. All but one patient had cen-
tral venous access. One had a native arteriovenous fistula.
Laboratory markers analyzed were: hematocrit, hemo-
globin, red and white blood cell count, platelet count, 
CH50, plasma fibrinogen as well as plasma IgG and IgM. 
All measurements were performed using routine laboratory 
tests using certified assay methods.
The following parameters were calculated: total blood 
volume (TBV) (TBV = weight × 70 mL/kg for male resp. 
weight × 65 mL/kg for female) and total plasma volume 
(TPV) (TPV = TBV × 1-hct), which was used for all fur-
ther analysis. The TPV was once compared with the TPV 
calculated by the Kaplan formula.
Processing time, plasma volume exchanged, blood flow, 
transmembrane pressure and removal bag volume were 
recorded. The reduction in the examined biomarkers (com-
paring pre- and post-TPE levels) was done by drawing 
the first sample from the vascular access site immediately 
before the start of treatment. Post-TPE samples were drawn 
from the vascular access site before rinse back was done. In 
addition we took samples from the removed and collected 
plasma in the waste bag to allow the measurement of the 
total removed biomarkers.
Statistical analysis
Data are presented as median and interquartile range (IQR). 
Comparisons between both techniques and between pre- 
and post-TPE laboratory marker levels were performed 
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using a paired t test. Differences were considered to be sta-
tistically significant if p values were <0.05.
Results
The average age of the patients was 51.6 ± 13.5 years. 
Ten (47.6 %) of them were females. The average BMI was 
25.1 ± 5.0 kg/m2. Underlying diseases necessitating TPE 
were humoral rejection after solid organ transplantation 
(n = 8); Guillian–Barré syndrome and variants (n = 3); 
monoclonal gammopathy (n = 2); multiple sclerosis 
(n = 2); microscopic polyangiitis (n = 2); rapid progres-
sive glomerulonephritis (n = 1); cryoglobulinemia (n = 1); 
and cytotoxic antibodies (n = 1). Further patients’ char-
acteristics and details of the procedure are described else-
where [15].
Out of the 21 patients, 20 could be retained for final 
analysis. One patient dropped out as only one treatment 
was performed. In the final 20 patients, 40 therapeutic 
TPEs were included in the final analysis. All treatments 
were well tolerated by the patients.
The median (IQR) total plasma volume based on the 
Nadler–Allen formula prior to the mTPE treatment was 
3045 (2771–3527) mL and did not differ from the plasma 
volume prior to the cTPE treatment where it was 2979 
(2752–3502) mL. Also the use of the Kaplan formula could 
not detect a difference in plasma volume between mTPE 
[3405 (2735–3820) mL] and the cTPE treatment [3229 
(2676–3872) mL].
Treatment time of the mTPE treatment was significantly 
longer 132.5 (125.0–148.8) min than the cTPE treatment 
[120.0 (114.3–138.0) min], Fig. 1a. This resulted in a lower 
plasma removal rate of the mTPE treatment 27.00 (25.25–
28.75) mL/min than during the cTPE treatment [30.00 
(26.25–32.50) mL/min Fig. 1b]. The processed blood 
volume required to remove 1.2 × total plasma volume in 
mTPE procedures was significantly higher than with cTPE 
(19.86 ± 3.42 versus 6.46 ± 1.23 L, p < 0.05). As a result, 
the plasma removal efficiency was significantly higher in 
cTPE than in mTPE (84 ± 11 versus 27 ± 5 %, p < 0.05). 
Both treatments were comparable in terms of decrease in 
IgG and IgM (Fig. 2). Also, the absolute amount of IgG and 
IgM was removed in mTPE (Fig. 2).
During the mTPE treatment, one circuit failure occurred, 
making a change of the system necessary. In another 
patient, a preemptive system change was performed due to 
an increase in TMP. The TMP in the mTPE group increased 
significantly from 14.0 (9.0–19.5) to 21.0 (13.5–26.0) 
mm Hg (p = 0.048). For the cTPE treatment, citrate was 
used as an anticoagulant with an inlet/AC ratio of 10/1. In 
these patients, we did not detect a difference in the ion-
ized calcium comparing the start and the end of treatment 
[1.17 (1.13–1.21) versus 1.13 (1.08–1.18) mmol/L; 
p = 0.126]. For mTPE, unfractionated heparin was used. 
Patients received a bolus injection of 2000 IU followed 
by a 1000 IU/h thereafter. Platelet loss during mTPE was 
nearly twice as high as with cTPE (15 ± 9 versus 7 ± 9 %, 
p < 0.05) (Table 1). While both hemoglobin level and hem-
atocrit remained unchanged in the mTPE treatment, there 
was a slight but significant increase in both parameters 
in the cTPE-treated patients (Table 1), possibly due to a 
hemoconcentration in the latter group. However, we do not 
have a patient weight before the rinse back, i.e., the time 
the blood sample was drawn.
Discussion
The pertinent findings of our study were that cTPE as com-
pared to mTPE provided a comparable treatment quality in 
a shorter period of time. To our knowledge, this is the first 
study directly comparing cTPE and mTPE.
Treatment time
Treatment time of mTPE was 10.4 % longer than for cTPE. 
Even though a median 13-min difference in treatment time 
can be almost neglected in centers that only rarely perform 
TPE, for high-volume centers like ours the amount of saved 
nursing time is substantial, in our case roughly 270 h per 
Fig. 1  a Procedure time during the mTPE and cTPE treatment. b 
Plasma removal rate during the mTPE and cTPE treatment
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year. This even holds true despite the fact that we kept 
the blood inlet flow in a range that is frequently observed 
in patients in whom peripheral veins are used for access. 
Hence the time saved by using cTPE instead of mTPE 
could have been even more substantial if the maximum 
blood flow in the central venous access allowed would have 
Fig. 2  Pre- and post-procedure plasma levels of IgG and fibrinogen and the corresponding total amount of these compounds in the removed 
plasma. Data are visualized as box-and-whisker plots (horizontal bars indicate median values)
Table 1  Laboratory parameters before and after mTPE and cTPE
* p < 0.05 comparing pre-and post-TPE values per treatment mode
Parameter Unit MTPE before MTPE after CTPE before CTPE after
Hematocrit % 33.90 (31.08–37.80) 32.79 (28.83–37.65) 33.85 (30.33–37.98) 34.95* (30.93–38.43)
Hemoglobin g/dL 11.30 (10.03–11.98) 10.90 (9.45–12.15) 11.10 (10.03–12.23) 11.50* (10.23–12.28)
PLT Mill/L 237.5 (176.3–310.0) 209.5* (141.5–254.5) 235.5 (174.0–284.8) 222.0* (151.0–293.0)
Leukocytes 103/µL 8.00 (3.92–11.43) 8.55* (5.47–13.3) 6.70 (4.82–13.03) 7.30* (5.37–13.95)
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been used. Therefore, it is very likely that in patients with 
a central line using higher inlet flow more cTPE would 
require even less time, i.e., would result in more substantial 
reduction in treatment time as compared to mTPE, a find-
ing of possible relevance to centers performing >50–100 
procedures a year, especially given the limited human and 
financial resources in the medical system.
Treatment quality
Aside from the treatment time, we investigated several 
parameters of treatment quality such as removal of IgG, 
IgM and fibrinogen as well as the effect of treatment modal-
ity on platelets and leukocytes. None of those parameters 
showed a marked difference. It is worthwhile to point out 
that this especially holds true for the platelet count, which 
decreased less in cTPE, arguing against a negative effect of 
cTPE which had been found three decades ago in cTPE [2]. 
Even though our study was not powered to compare inci-
dence of circuit failure, we did not observe a circuit failure 
during the cTPE treatments. The underlying reason might 
have been the routine use of citrate anticoagulation, whose 
main advantage is the reduction in bleeding risk [8]. Other 
authors have even attributed a modulating effect on the 
immunes system with the use of citrate [10]. In a subgroup 
of 10 patients, we could, however, not detect a different 
effect on the complement system using the CH50 test. It is 
important to point out that none of the cTPE patients expe-
rienced clinical or laboratory side effects, i.e., hypocalce-
mia. By contrast, during the mTPE treatment we observed 
one circuit clotting. Two circuits had been preemptively 
changed due to a rise in transmembrane pressure. This 
potential difference in circuit failure rate between cTPE 
and mTPE should be investigated in larger studies. Moreo-
ver, it would be of interest to elucidate which role the sole 
use of unfractionated heparin has in this regard.
Limitations of the study
There are several limitations of our study that we wish to 
point out. We performed a single-center study in a lim-
ited number of patients. Nonetheless, due to the crosso-
ver design of our study, every patient served as his/her 
own control. Moreover, we did not use peripheral veins 
as access, an access site frequently used in the outpatient 
setting, yet our inlet flow is in the range frequently used 
in this setting, and thus, our data are representative of this 
patient population. On the other hand, we did not use the 
maximum inlet flow that would have been possible with 
a central venous access, thus representing a bias underes-
timating the possible performance of the cTPE. Further, 
we only analyzed treatment time, but not time for machine 
set-up and related activities. Lastly, our study was neither 
aimed nor powered to evaluate procedure-related com-
plications, let alone clinical outcome. In summary, espe-
cially for units performing frequent TPEs, cTPE with its 
shorter treatment might be the preferred mode over mTPE, 
yet other factors such as technical experiences with the 
techniques, learning curve of the staff as well as off-hour 
procedures and the price of disposables also impact this 
decision.
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